新型口服抗凝药在非瓣膜性房颤中的应用进展

目的:对新型口服抗凝药(NOACs)在非瓣膜性房颤抗凝治疗中的临床应用和发展进行探讨。方法:收集最新发表的相关文章,对新型口服抗凝药的药理学特性、临床试验结果和临床应用进行分析总结。结果与结论:房颤是临床中最常见的心律失常,对于CHA_2DS_2-VASc评分≥2或既往曾有一过性脑缺血发作(TIA)或有卒中史的患者,应该使用抗凝药物。新型口服抗凝药,与维生素K拮抗剂(VKA)相比,有相似甚至更好的抗凝效果、安全性和便利性。它们具有快速起效,更多可预测的药动学特征,与其他药物相互作用少,饮食对其无明显影响,比华法林导致颅内出血的风险更低。

Progress of novel oral anticoagulants in non-valvular atrial fibrillation

Objective:To review the recent progress of new oral anticoagulants in anticoagulation treatment for non-valve atrial ifbrillation.Methods: We collected the latest researches related to anticoagulation treatment with NOACs, and then gave the analysis and summary.Results and Conclusion:Atrial fibrillation is the most frequent arrhythmia in clinical practice. The use of anticoagulants is indicated if CHA2DS2-VASc score≥2 or in patients with previous transient ischemic attack or stroke. Recently, novel oral anticoagulants (NOACs) have been introduced, offering similar (or better) effectiveness, safety, and convenience than vitamin K antagonists. They display rapid onset of action, more predictable of pharmacological proifle, less interactions with other drugs, lack of signiifcant effects in the diet, and less risk of intracranial hemorrhage than warfarin.